IDXX logo

IDEXX LABORATORIES INC

IDXXNASDAQ
πŸ† #264 by market capEarnings Nov 2 Β· PreUS Equity
$586.64β–Ό $8.98 (βˆ’1.53%)
πŸŒ™ After hours$586.65β–² 0.00%Regular close Β· extended-hours price shown
1hβ€”
24hβ–Ό 1.5%
7dβ–² 0.3%
14dβ–² 2.9%
30dβ–² 3.9%
1yβ–Ό 10.0%
🏦Market Cap
$46.27B
Mid Cap
πŸ“ˆRevenue Growth (YoY)
+12.8%
Healthy
πŸ“ŠGross Margin
62.5%
High
πŸ’΅FCF Margin
27.2%
Strong
βš–οΈP/S Ratio
10.4x
Elevated
Otter Score
58
Weak

Trading Snapshot

Day Range
$578.50 – $590.34
52-Week Range
$518.55 – $769.98
Volume
$3.69B
Avg Volume
$3.56B
Shares Outstanding
78.9M
Next Earnings
Sep 23, 2026

Fundamentals Snapshot

Annual Revenue
$4.30B
Last Q Revenue
$1.22B
P/E Ratio
41.4
P/S Ratio
10.4x
EPS (TTM)
$14.23
Dividend Yield
β€”

Why Investors Own IDXX

  • βœ“High-growth profile β€” revenue up +46.2% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 75% gross margin and 15% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)
$4.30Bβ–² +42.0% YoY
Gross Margin (TTM)
74.5%β–² +3.2% YoY
Operating Income (TTM)
$366Mβ–² +42.0% YoY
Free Cash Flow (TTM)
$663Mβ–² +42.0% YoY

About IDEXX LABORATORIES INC

IDEXX Laboratories, Inc. is a global enterprise focused on creating, producing, and distributing a wide array of products and services. Its primary client base includes companion animal veterinary practices, the livestock and poultry industries, dairy operations, and water quality testing sectors. The company organizes its operations across several key divisions: the Companion Animal Group (CAG), Water Quality Products, Livestock, Poultry, and Dairy (LPD), and additional segments. For companion animals, IDEXX offers a comprehensive suite of point-of-care veterinary diagnostic tools, such as instruments, consumables, and rapid assay kits. It also provides reference laboratory diagnostic and consultation services, alongside practice management and diagnostic imaging solutions for veterinarians. Furthermore, the company supports the biomedical research community with health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services. In the livestock, poultry, and dairy markets, IDEXX supplies diagnostic and health-monitoring solutions. Its water testing portfolio includes products designed to detect various microbiological contaminants, notably the Colilert, Colilert-18, and Colisure tests for total coliforms and E. coli, as well as Enterolert, Pseudalert, Filta-Max, Filta-Max xpress, Legiolert, and Quanti-Tray products. Beyond these, IDEXX extends its reach to human point-of-care medical diagnostics, offering electrolyte and blood gas analyzers, and SARS-CoV-2 RT-PCR tests. Other key offerings encompass in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers, as well as SNAP rapid assay test kits. Veterinary software and services for both independent clinics and large corporate veterinary groups are also part of its offerings. The company distributes its extensive product and service catalog through its own dedicated marketing, customer service, sales, and technical service teams, supplemented by independent distributors and other resellers. IDEXX Laboratories, Inc. was established in 1983 and maintains its headquarters in Westbrook, Maine.

🦦

Otter Score Breakdown

β“˜
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
Overall Score
Weak
58/100

Analyst Price Target

β“˜
Average Target
$721.13
β–² +22.9% Upside
High Target$882.25
Low Target$601.20
Based on 14 analysts

Latest News & Updates